Compare FT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FT | ACIU |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.6M | 213.3M |
| IPO Year | N/A | 2016 |
| Metric | FT | ACIU |
|---|---|---|
| Price | $7.84 | $2.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 63.0K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 7.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,482,957.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $738.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.97 | $1.43 |
| 52 Week High | $7.23 | $4.00 |
| Indicator | FT | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 47.78 |
| Support Level | $7.79 | $2.54 |
| Resistance Level | $7.91 | $3.45 |
| Average True Range (ATR) | 0.10 | 0.30 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 12.50 | 31.75 |
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.